ONCBeOne MedicinesRunning, no new patients
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 94 (planned)
- Started
- Nov 14, 2024
- Main results expected
- Nov 2026
- Fully finished
- Sep 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Complete Response (CR)/ Complete Response with Incomplete Bone Marrow Recovery (CRi) Rate
Measured over: Month 16
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06637501 · record last updated 2026-07-09 · checked 2026-11-09 15:47 UTC